EQRX News and Press, EQRx Inc. From 05/08/23

2023-05-08 22:57:09 ET EQRx, Inc. (EQRX) Q1 2023 Earnings Conference Call May 8, 2023 16:30 ET Company Participants Michelle Greenblatt - Head of Investor Relations Melanie Nallicheri - President & Chief Executive Officer Eric Hedrick - Chief Physician Execut...

2023-05-08 16:43:24 ET EQRx press release ( NASDAQ: EQRX ): Q1 GAAP EPS of -$0.17 misses by $0.03 . For further details see:  EQRx GAAP EPS of -$0.17 misses by $0.03

Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapies Prioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first...

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today an...

2023-03-13 09:29:42 ET EQRx ( NASDAQ: EQRX ), a biotech focused on oncology and immune-inflammatory diseases fell ~3% pre-market Monday after announcing the resignation of Jami Rubin, its Chief Financial Officer as well as principal financial officer and principal accounti...

EQRx press release ( NASDAQ: EQRX ): Q4 GAAP EPS of -$0.05 beats by $0.14 . Ended 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 2028 For further details see:  EQRx GAAP EPS of -$0.05 beats by $0.14

For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemal...

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today ann...

Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancer Acceptance of the marketing authorization application (MAA) is EQRx’s second from the United ...

Submission is EQRx’s first to European Medicines Agency Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -...